Yuna Blum

Prof. Yuna Blum

Institute of Genetics & Development in Rennes, UMR6290 CNRS

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
FPFrancesco Puleo
Francesco Puleo
RNRemy Nicolle
Remy Nicolle
YBYuna Blum
Yuna Blum
Jerome CrosJerome Cros
Jerome Cros
LMLaetitia Marisa
Laetitia Marisa
RMRaphaël Maréchal
Raphaël Maréchal

13 April 2017 in Genome Biology
Verified
Journal Article
Open access
PDF file
EOElin Org
Elin Org
YBYuna Blum
Yuna Blum
SKSilva Kasela
Silva Kasela
MMMargarete Mehrabian
Margarete Mehrabian
JKJohanna Kuusisto
Johanna Kuusisto
ALAldons J. Lusis
Aldons J. Lusis
The gut microbiome is a complex and metabolically active community that directly influences host phenotypes. In this study, we profile gut microbiota using 16S rRNA gene sequencing in 531 well-phenotyped Finnish men from the Metabolic Syndrome In Men (METSIM) study. We investigate gut microbiota relationships with a variety of factors that have an impact on the development of metabolic and cardiovascular traits. We identify novel associations between gut microbiota and fasting serum levels of a number of metabolites, including fatty acids, amino acids, lipids, and glucose. In particular, we detect associations with fasting plasma trimethylamine N-oxide (TMAO) levels, a gut microbiota-dependent metabolite associated with coronary artery disease and stroke. We further investigate the gut microbiota composition and microbiota–metabolite relationships in subjects with different body mass index and individuals with normal or altered oral glucose tolerance. Finally, we perform microbiota co-occurrence network analysis, which shows that certain metabolites strongly correlate with microbial community structure and that some of these correlations are specific for the pre-diabetic state. Our study identifies novel relationships between the composition of the gut microbiota and circulating metabolites and provides a resource for future studies to understand host–gut microbiota relationships.

17 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Gwen LomberkGwen Lomberk
Gwen Lomberk
YBYuna Blum
Yuna Blum
RNRemy Nicolle
Remy Nicolle
ANAsha Nair
Asha Nair
KGKrutika Satish Gaonkar
Krutika Satish Gaonkar
RURaul A. Urrutia
Raul A. Urrutia
Recent studies have offered ample insight into genome-wide expression patterns to define pancreatic ductal adenocarcinoma (PDAC) subtypes, although there remains a lack of knowledge regarding the underlying epigenomics of PDAC. Here we perform multi-parametric integrative analyses of chromatin immunoprecipitation-sequencing (ChIP-seq) on multiple histone modifications, RNA-sequencing (RNA-seq), and DNA methylation to define epigenomic landscapes for PDAC subtypes, which can predict their relative aggressiveness and survival. Moreover, we describe the state of promoters, enhancers, super-enhancers, euchromatic, and heterochromatic regions for each subtype. Further analyses indicate that the distinct epigenomic landscapes are regulated by different membrane-to-nucleus pathways. Inactivation of a basal-specific super-enhancer associated pathway reveals the existence of plasticity between subtypes. Thus, our study provides new insight into the epigenetic landscapes associated with the heterogeneity of PDAC, thereby increasing our mechanistic understanding of this disease, as well as offering potential new markers and therapeutic targets.

1 November 2017 in Cell Reports
Verified
Journal Article
Open access
RNRemy Nicolle
Remy Nicolle
YBYuna Blum
Yuna Blum
LMLaetitia Marisa
Laetitia Marisa
CLCeline Loncle
Celine Loncle
OGOdile Gayet
Odile Gayet
JIJuan Iovanna
Juan Iovanna
Preclinical models based on patient-derived xenografts have remarkable specificity in distinguishing transformed human tumor cells from non-transformed murine stromal cells computationally. We obtained 29 pancreatic ductal adenocarcinoma (PDAC) xenografts from either resectable or non-resectable patients (surgery and endoscopic ultrasound-guided fine-needle aspirate, respectively). Extensive multiomic profiling revealed two subtypes with distinct clinical outcomes. These subtypes uncovered specific alterations in DNA methylation and transcription as well as in signaling pathways involved in tumor-stromal cross-talk. The analysis of these pathways indicates therapeutic opportunities for targeting both compartments and their interactions. In particular, we show that inhibiting NPC1L1 with Ezetimibe, a clinically available drug, might be an efficient approach for treating pancreatic cancers. These findings uncover the complex and diverse interplay between PDAC tumors and the stroma and demonstrate the pivotal role of xenografts for drug discovery and relevance to PDAC.

22 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YBYuna Blum
Yuna Blum
CMClément Meiller
Clément Meiller
LQLisa Quetel
Lisa Quetel
NENabila Elarouci
Nabila Elarouci
MAMira Ayadi
Mira Ayadi
DJDidier Jean
Didier Jean
Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Molecular profiling studies have not addressed intra-tumor heterogeneity in MPM to date. Here, we use a deconvolution approach and show that molecular gradients shed new light on the intra-tumor heterogeneity of MPM, leading to a reconsideration of MPM molecular classifications. We show that each tumor can be decomposed as a combination of epithelioid-like and sarcomatoid-like components whose proportions are highly associated with the prognosis. Moreover, we show that this more subtle way of characterizing MPM heterogeneity provides a better understanding of the underlying oncogenic pathways and the related epigenetic regulation and immune and stromal contexts. We discuss the implications of these findings for guiding therapeutic strategies, particularly immunotherapies and targeted therapies.

16 February 2016 in Scientific Reports
Verified
Journal Article
Open access
AMAlexandra Montagner
Alexandra Montagner
AKAgata Korecka
Agata Korecka
APArnaud Polizzi
Arnaud Polizzi
YLYannick Lippi
Yannick Lippi
YBYuna Blum
Yuna Blum
Walter WahliWalter Wahli
Walter Wahli
The liver is a key organ of metabolic homeostasis with functions that oscillate in response to food intake. Although liver and gut microbiome crosstalk has been reported, microbiome-mediated effects on peripheral circadian clocks and their output genes are less well known. Here, we report that germ-free (GF) mice display altered daily oscillation of clock gene expression with a concomitant change in the expression of clock output regulators. Mice exposed to microbes typically exhibit characterized activities of nuclear receptors, some of which (PPARα, LXRβ) regulate specific liver gene expression networks, but these activities are profoundly changed in GF mice. These alterations in microbiome-sensitive gene expression patterns are associated with daily alterations in lipid, glucose and xenobiotic metabolism, protein turnover and redox balance, as revealed by hepatic metabolome analyses. Moreover, at the systemic level, daily changes in the abundance of biomarkers such as HDL cholesterol, free fatty acids, FGF21, bilirubin and lactate depend on the microbiome. Altogether, our results indicate that the microbiome is required for integration of liver clock oscillations that tune output activators and their effectors, thereby regulating metabolic gene expression for optimal liver function.